Woman in Washington dies from a rare blood clotting syndrome after taking Johnson & Johnson vaccine

Getting your Trinity Audio player ready...

Washington, D.C., United States: As per to the Seattle and King County Public Health, a woman in her late 30s died from a rare blood clotting syndrome after taking a dose of the Johnson &Johnson COVID-19 vaccine.

CDC and United States Food & Drug administration suggested a halt to the use of the WHO-approved J&J novel coronavirus vaccine.

This recommendation was made after a small number of individuals reported blood clots which mostly included women less than 50 years.

But green light for the intake of the Johnson &Johnson COVID-19 vaccine was resumed shortly after but with a further warning of the blood clots risk.

This has also engraved fear among the people who have taken the particular COVID-19 vaccine.

Seattle & King County stated that the diagnosis was confirmed by the US Centers for Disease Control and Prevention’s Clinical Immunization Safety Assessment Project. CDC has reported 3 other confirmed TTS deaths nationally, the release further noted.

The local health agency did not identified the woman who died. But earlier this month, the website of the Oregonian newspaper published an obituary for 37-year-old Seattle resident Jessica Berg Wilson that asserted she died September 7 from a rare vaccine-induced blood clotting syndrome.

In their statement, CDC stated that it was aware of the case, and the report “indicates a ‘plausible causal relationship’ between the J&J/Janssen COVID-19 Vaccine and TTS.” The agency said it would release updated information on TTS cases later this year.

Health authorities have stated that Johnson & Johnson was safe and effective, and the benefits of the single-shot vaccine far outpaced the risks.

CDC stated that people who received the Johnson & Johnson vaccine should look out for symptoms of a blood clot with low platelets for several weeks after vaccination and should take medical care immediately if they identify any. Symptoms includes – “severe or persistent headaches or blurred vision, shortness of breath, chest pain, leg swelling, persistent abdominal pain” and “easy bruising or tiny blood spots under the skin beyond the injection site.”